These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1387417)

  • 1. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
    Straw JA; Loo TL; de Vera CC; Nelson PD; Tompkins WA; Bai SA
    J Acquir Immune Defic Syndr (1988); 1992; 5(9):936-42. PubMed ID: 1387417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related differences in pharmacokinetics of phosphonoformate in cats.
    Swenson CL; Sams RA; Polas PJ; Michael DF; Mathes LE
    Antimicrob Agents Chemother; 1990 May; 34(5):871-4. PubMed ID: 2141779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
    Jacobson MA; Crowe S; Levy J; Aweeka F; Gambertoglio J; McManus N; Mills J
    J Infect Dis; 1988 Oct; 158(4):862-5. PubMed ID: 2844921
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
    Aweeka F; Gambertoglio J; Mills J; Jacobson MA
    Antimicrob Agents Chemother; 1989 May; 33(5):742-5. PubMed ID: 2546491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
    Sjövall J; Karlsson A; Ogenstad S; Sandström E; Saarimäki M
    Clin Pharmacol Ther; 1988 Jul; 44(1):65-73. PubMed ID: 2968875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
    Hussain AS; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1989 Feb; 11(2):111-4. PubMed ID: 2523506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
    Sjövall J; Bergdahl S; Movin G; Ogenstad S; Saarimäki M
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1023-31. PubMed ID: 2528939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
    Noormohamed FH; Youle MS; Higgs CJ; Martin-Munley S; Gazzard BG; Lant AF
    Antimicrob Agents Chemother; 1998 Feb; 42(2):293-7. PubMed ID: 9527775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of PFA (trisodium phosphonoformate) after i.v. and p.o. administration to beagle dogs and rabbits.
    Ritschel WA; Grummich KW; Hussain SA
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):41-8. PubMed ID: 3157841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foscarnet sodium.
    Minor JR; Baltz JK
    DICP; 1991 Jan; 25(1):41-7. PubMed ID: 1848959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics.
    Dusserre N; Lessard C; Paquette N; Perron S; Poulin L; Tremblay M; Beauchamp D; Désormeaux A; Bergeron MG
    AIDS; 1995 Aug; 9(8):833-41. PubMed ID: 7576316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
    Farthing CF; Dalgleish AG; Clark A; McClure M; Chanas A; Gazzard BG
    AIDS; 1987 May; 1(1):21-5. PubMed ID: 2962589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
    MacGregor RR; Graziani AL; Weiss R; Grunwald JE; Gambertoglio JG
    J Infect Dis; 1991 Oct; 164(4):785-7. PubMed ID: 1654363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
    Baltz JK; Kennedy P; Minor JR; Gallelli J
    Am J Hosp Pharm; 1990 Sep; 47(9):2075-7. PubMed ID: 2145761
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro.
    Swenson CL; Polas PJ; Cheney CM; Kociba GJ; Mathes LE
    Am J Vet Res; 1991 Dec; 52(12):2010-5. PubMed ID: 1724122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology: foscarnet.
    Lietman PS
    Am J Med; 1992 Feb; 92(2A):8S-11S. PubMed ID: 1371039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
    Erlich KS; Jacobson MA; Koehler JE; Follansbee SE; Drennan DP; Gooze L; Safrin S; Mills J
    Ann Intern Med; 1989 May; 110(9):710-3. PubMed ID: 2522751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
    Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY
    Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foscarnet.
    Med Lett Drugs Ther; 1992 Jan; 34(861):3-4. PubMed ID: 1309469
    [No Abstract]   [Full Text] [Related]  

  • 20. Foscarnet and extended survival in AIDS patients.
    Am Fam Physician; 1991 Dec; 44(6):2244. PubMed ID: 1836090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.